The approval covers all 27 European Union member states. Tresiba (insulin degludec) is a once-daily new-generation based insulin analogue with an ultra-long duration of action. Ryzodeg (insulin ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.